Genetic Technologies Limi... (GENE)
0.77
0.01 (0.65%)
At close: Nov 14, 2024, 9:00 PM
0.65% (1D)
| Bid | n/a |
| Market Cap | 111.24M |
| Revenue (ttm) | 13.29M |
| Net Income (ttm) | -18.31M |
| EPS (ttm) | -0.02 |
| PE Ratio (ttm) | -38.25 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | n/a |
| Volume | 0 |
| Avg. Volume (20D) | 0 |
| Open | undefined |
| Previous Close | 0.77 |
| Day's Range | 0.77 - 0.77 |
| 52-Week Range | 0.67 - 3.59 |
| Beta | 0.48 |
About GENE
Genetic Technologies Limited, a molecular diagnostics company, provides predictive testing and assessment tools to help physicians manage women's health in Australia and the United States. The company's lead product is the BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It also markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecol...
Industry Medical - Diagnostics & Research
Sector Healthcare
IPO Date Sep 6, 2005
Employees 55
Stock Exchange NASDAQ
Ticker Symbol GENE
Website https://www.gtglabs.com
